Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells

European Cytokine Network

Volumn 18, Issue 3, 2007, Pages 120-126

  Collette, Madeleine ^a   Descamps, Géraldine ^a   Pellat Deceunynck, Catherine ^a   Bataille, Régis ^a   Amiot, Martine ^a  

^a INSTITUT DE BIOLOGIE   (France)

Author keywords

CD45; Clonogenicity; IGF 1; IL 6; Multiple myeloma

Indexed keywords

CD45 ANTIGEN; FIBROBLAST GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATASE; SCATTER FACTOR; SOMATOMEDIN C;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CLONOGENESIS; CLONOGENIC ASSAY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MYELOMA CELL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANTIGENS, CD45; CELL DIVISION; CELL LINE; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPATOCYTE GROWTH FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 35348860176     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2007.0095     Document Type: Article

References (21)

1. Bataille R, Harousseau J-L. Multiple Myeloma. Recent advances in the biology and management. New Engl J Med 1997; 336: 1657.
2. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1998; 332: 83.
3. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517.
4. Georgii-Hemming P, Wiklund HJ, Ljunggren O, et al. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 1996; 88: 2250.
5. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 2856.
6. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000; 60: 6763.
7. Hideshima T, Nakamura N, Chauhan D, et al. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991.
8. Descamps G, Pellat-Deceunynck C, Szpak Y, et al. The magnitude of Akt/phosphatidylinositol 3′-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J Immunol 2004; 173: 4953.
9. Moreau P, Robillard N, Avet-Loiseau H, et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004; 89: 547.
10. Kulas DT, Freund GG, Mooney RA. The transmembrane protein-tyrosine phosphatase CD45 is associated with decreased insulin receptor signaling. J Biol Chem 1996; 271: 755.
11. Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003; 78: 106.
12. Bataille R, Jégo G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myeloma" and of new targets for myeloma therapy. Haematologica 2006; 91: 1234.
13. Bataille R, Robillard N, Avet-Loiseau H, et al. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 2005; 90: 706.
14. Abroun S, Ishikawa H, Tsuyama N, et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha. Blood 2004; 103: 2291.
15. Barille S, Bataille R, Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw 2000; 11: 546.
16. Heinrich PC, Behrmann I, Muller-Newen G, et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334: 297.
17. Ishikawa H, Tsuyama N, Kawano MM. Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules. Int J Hematol 2003; 78: 95.
18. Ishikawa H, Tsuyama N, Abroun S, et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 2002; 99: 2172.
19. Li FJ, Tsuyama N, Ishikawa H, et al. A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma. Blood 2005; 105: 3295.
20. Ishikawa H, Tsuyama N, Liu S, et al. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene 2005; 24: 6328.
21. Wang YD, De Vos J, Jourdan M, et al. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 2002; 21: 2584.